Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut AllergyMatthew Greenhawt, Paul Turner, Sayantani Sindher et al.|New England Journal of Medicine|2023Cited by 129
CRISPR-based gene editing enables <i>FOXP3</i> gene repair in IPEX patient cellsMarianne Goodwin, Rosa Bacchetta, Mansi Narula et al.|Science Advances|2020Cited by 113
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEMatthew Greenhawt, Christian Vogelberg, Deborah Albright et al.|The Journal of Allergy and Clinical Immunology In Practice|2025Cited by 14